These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 17975981)

  • 1. Evaluation of a novel immunomodulator composed of human chorionic gonadotropin and bacillus Calmette-Guerin for treatment of canine mast cell tumors in clinically affected dogs.
    Henry CJ; Downing S; Rosenthal RC; Klein MK; Meleo K; Villamil JA; Fineman LS; McCaw DL; Higginbotham ML; McMichael J
    Am J Vet Res; 2007 Nov; 68(11):1246-51. PubMed ID: 17975981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy and safety of a water-soluble micellar paclitaxel (Paccal Vet) in canine mastocytomas.
    Rivera P; Akerlund-Denneberg N; Bergvall K; Kessler M; Rowe A; Willmann M; Persson G; Kastengren Fröberg G; Westberg S; von Euler H
    J Small Anim Pract; 2013 Jan; 54(1):20-7. PubMed ID: 23190121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Canine conjunctival mast cell tumors: a retrospective study.
    Fife M; Blocker T; Fife T; Dubielzig RR; Dunn K
    Vet Ophthalmol; 2011 May; 14(3):153-60. PubMed ID: 21521438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological behavior of oral and perioral mast cell tumors in dogs: 44 cases (1996-2006).
    Hillman LA; Garrett LD; de Lorimier LP; Charney SC; Borst LB; Fan TM
    J Am Vet Med Assoc; 2010 Oct; 237(8):936-42. PubMed ID: 20946081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haematologic toxicity in dogs with mast cell tumours treated with vinblastine/prednisolone chemotherapy with/without radiotherapy.
    Stiborova K; Treggiari E; Amores-Fuster I; Del Busto I; Killick D; Maddox T; Marrington M; Mason SL; Blackwood L
    J Small Anim Pract; 2019 Sep; 60(9):534-542. PubMed ID: 31245847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective review of treatment and response of high-risk mast cell tumours in dogs.
    Miller RL; Van Lelyveld S; Warland J; Dobson JM; Foale RD
    Vet Comp Oncol; 2016 Dec; 14(4):361-370. PubMed ID: 25223579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Redox status evaluation in dogs affected by mast cell tumour.
    Finotello R; Pasquini A; Meucci V; Lippi I; Rota A; Guidi G; Marchetti V
    Vet Comp Oncol; 2014 Jun; 12(2):120-9. PubMed ID: 22823560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: a phase I dose-finding study.
    Robat C; London C; Bunting L; McCartan L; Stingle N; Selting K; Kurzman I; Vail DM
    Vet Comp Oncol; 2012 Sep; 10(3):174-83. PubMed ID: 22235914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Additional information on the behavior of oral mast cell tumors.
    Hoffman S
    J Am Vet Med Assoc; 2010 Dec; 237(12):1368. PubMed ID: 21229804
    [No Abstract]   [Full Text] [Related]  

  • 10. Compartment syndrome associated with expansile antebrachial tumors in two dogs.
    Maki LC; Kim SE; Winter MD; Kow KY; Conway JA; Lewis DD
    J Am Vet Med Assoc; 2014 Feb; 244(3):346-51. PubMed ID: 24432967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vinblastine/prednisolone chemotherapy leads to hematological toxicity in dogs with high-grade or metastatic mast cell tumors.
    Soussa RW; Jaderberg S; Williams TL; Dobson JM
    J Am Vet Med Assoc; 2024 Jun; ():1-9. PubMed ID: 38906172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcutaneous mast cell tumours: A prospective multi-institutional clinicopathological and prognostic study of 43 dogs.
    Marconato L; Stefanello D; Solari Basano F; Faroni E; Dacasto M; Giantin M; Bettini G; Aresu L; Bonfanti U; Bertazzolo W; Annoni M; Lecchi C; Sabattini S
    Vet Rec; 2023 Jul; 193(1):e2991. PubMed ID: 37224084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination vinblastine and palladia for high-grade and metastatic mast cell tumors in dogs.
    Todd JE; Nguyen SM; White J; Langova V; Thomas PM; Tzannes S
    Can Vet J; 2021 Dec; 62(12):1335-1340. PubMed ID: 34857971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone.
    Macedo TR; de Queiroz GF; Casagrande TAC; Alexandre PA; Brandão PE; Fukumasu H; Melo SR; Dagli MLZ; Pinto ACBCF; Matera JM
    Cells; 2022 Feb; 11(3):. PubMed ID: 35159380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative oncology: The paradigmatic example of canine and human mast cell neoplasms.
    Willmann M; Hadzijusufovic E; Hermine O; Dacasto M; Marconato L; Bauer K; Peter B; Gamperl S; Eisenwort G; Jensen-Jarolim E; Müller M; Arock M; Vail DM; Valent P
    Vet Comp Oncol; 2019 Mar; 17(1):1-10. PubMed ID: 30136349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination vinblastine, prednisolone and toceranib phosphate for treatment of grade II and III mast cell tumours in dogs.
    Olsen JA; Thomson M; O'Connell K; Wyatt K
    Vet Med Sci; 2018 May; 4(3):237-51. PubMed ID: 29797551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability of a rapid-escalation vinblastine-prednisolone protocol in dogs with mast cell tumours.
    Serra Varela JC; Pecceu E; Handel I; Lawrence J
    Vet Med Sci; 2016 Nov; 2(4):266-280. PubMed ID: 29067202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine kinase inhibitors as an alternative treatment in canine mast cell tumor.
    Coelho YNB; Soldi LR; da Silva PHR; Mesquita CM; Paranhos LR; Dos Santos TR; Silva MJB
    Front Vet Sci; 2023; 10():1188795. PubMed ID: 37360406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study.
    London CA; Gardner HL; Mathie T; Stingle N; Portela R; Pennell ML; Clifford CA; Rosenberg MP; Vail DM; Williams LE; Cronin KL; Wilson-Robles H; Borgatti A; Henry CJ; Bailey DB; Locke J; Northrup NC; Crawford-Jakubiak M; Gill VL; Klein MK; Ruslander DM; Thamm DH; Phillips B; Post G
    PLoS One; 2015; 10(4):e0124889. PubMed ID: 25923466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of local, regional and abscopal effects of Boron Neutron Capture Therapy (BNCT) combined with immunotherapy in an ectopic colon cancer model.
    Trivillin VA; Langle YV; Palmieri MA; Pozzi ECC; Thorp SI; Benitez Frydryk DN; Garabalino MA; Monti Hughes A; Curotto PM; Colombo LL; Santa Cruz IS; Ramos PS; Itoiz ME; Argüelles C; Eiján AM; Schwint AE
    Br J Radiol; 2021 Dec; 94(1128):20210593. PubMed ID: 34520668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.